Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978183 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02978183: Completed Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
NCT02978183 is a Phase 2 study that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02978183, a Phase 2 study, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
Primary Outcome
Ocular itching evaluated by the subject. Ocular itching was evaluated on a 0-4 scale (with half unit increments allowed). Lower scores indicated less itching.
Interventions
- BIOLOGICAL ST266
- DRUG Saline (0.9% NaCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
What the finished NCT02978183 record still lists
NCT02978183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which ST266 is the first listed.
NCT02978183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02978183 about?
NCT02978183 is a clinical study titled "Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis". The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
What is the current status of trial NCT02978183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-12. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02978183?
The interventions under investigation include: ST266 (BIOLOGICAL), Saline (0.9% NaCl) (DRUG).
Who is sponsoring clinical trial NCT02978183?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02978183's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia